Alzheimer's disease and melatonin

Etsuro Matsubara, Mikio Shoji, Tetsuro Murakami, Takeshi Kawarabayashi, Koji Abe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

Original languageEnglish
Pages (from-to)395-398
Number of pages4
JournalInternational Congress Series
Volume1252
Issue numberC
DOIs
Publication statusPublished - Jun 1 2003

    Fingerprint

Keywords

  • Alzheimer's disease
  • Amyloid β
  • Anti-amyloidogenic properties of melatonin
  • Antioxidant properties of melatonin
  • Melatonin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Matsubara, E., Shoji, M., Murakami, T., Kawarabayashi, T., & Abe, K. (2003). Alzheimer's disease and melatonin. International Congress Series, 1252(C), 395-398. https://doi.org/10.1016/S0531-5131(03)00019-0